Skip to main content

Drug Safety

Dr. John Cush
@RheumNow
New Treatment for Fibromyalgia? Will It Help or Harm? For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY
Adela Castro
@AdelaCastro222
Is it the treatment or the disease? -Multiple meds can cause SCLE: more widespread, EM,Bullous features. -Dupilumab can cause enthesitis: if severe needs dc of medication -Anti-CD 20 may cause IBD (Crohn’s-Like) Great lecture from @md_chawla on Drug induced syndromes #ACR26 https://t.co/EEQL7QNtWC
Antoni Chan MD (Prof)
@synovialjoints
Reflection on sequencing: antibody status and patient factors predicted outcome more than mechanism, TNFi cycling was the most common switch in the last 2 decades, and Leeds data suggest some treatment failure may be iatrogenic. @rheumnow #ACR26 Abstract#2284 Abstract#1324
Mrinalini Dey
@DrMiniDey
Rituximab in RA: low IgG was associated with serious infection (HR 6.25 after baseline-IgG adjustment; 95% CI 2.54-15.39). Longitudinal IgG monitoring before each RTX cycle is suggested based on these data. @Rheumnow #2931 #ACR26
Mike Putman
@EBRheum
New drug coming to myositis w/data in immune-mediated necrotizing phenotypes (IMNM) ALKIVIA phase 3 RCT randomized 175 pts to FcRn blocker efgartigimod or PLBO Improved total improvement score (TIS) at wk52 & TIS >=40; also increased serious AEs (21% vs 14% PLBO) Interesting https://t.co/Dqh8Sh9mew
Jiha Lee
@JihaRheum
A#2929 JAKi vs TNFi in RA (TriNetX, N>32k): mortality HR 1.28 at 3yr, yet MACE null until 5yr (HR 1.06). Mortality ahead of MACE may reflect non-CV deaths? Channeling, confounding by indication and switchers may bias the comparison @rheumnow #ACR26
Janet Pope
@Janetbirdope
NEW #MOA in #SLE TLR7/8 #Afimetoran Drives Interferon T1 TLR7 Changes organ damage TLR8 1 or more background #lupus #Rx mandated #prednisone taper Aim <7.5mg/d #GCs Mean #SLEDAI 8, CLASI 7-8 Mean pred 9.5-10.5 85%HCQ #ACR26 @RheumNow @ACRheum #LB24 https://t.co/EXCnYdc7O3
sheila
@RHEUMarampa
TARA trial: Ph3 H2H trial of Girocitinib (JAK1/TYK2i) vs Tofa in RA refractory to bDMARDs Giro achieved higher ACR50 response vs Tofa at wk24 (73 vs 49.5%) Also met secondary endpts Safety data: Infections more common. No VT/malignancy/MACE in Giro arm. @RheumNow #ACR26 LB21 https://t.co/HNVt7WdLc6
Eric Dein
@ericdeinmd
Ab#2547 #ACR26 @RheumNow Sublingual cylcobenzaprine - now approved for Fibro RELIEF, RESILIENT trials: NNT (# needed for >30% pain reduction) = 7 NNH (# needed for one Rx d/c due AEs) = 26 LHH (NNH/NNL) = 3.7, suggests nearly 4x likelihood of benefit to harm
Dr. John Cush
@RheumNow
2 Weeks off Methotrexate Boosts Zoster Response Consider holding methotrexate for two weeks after each recombinant zoster vaccine dose when disease is stable, and give the vaccine before rituximab when timing allows. Those are the messages from a pair of abstracts presented by https://t.co/qeEQp0LeHB
Audrey Gibson
@Gibson_RheumPAC
Dörner et al: The NEPTUNUS extension examines longer-term ianalumab treatment in Sjögren's disease after positive phase 3 trials. Durability, safety and sustained disease control are the questions to watch. @rheumnow #ACR2026 Abstract#LB14
×